Literature DB >> 21770994

A follow-up study of peri-implantitis cases after treatment.

Georgios Charalampakis1, Per Rabe, Asa Leonhardt, Gunnar Dahlén.   

Abstract

AIM: The aim of this retrospective study was to follow patient cases in a longitudinal manner after peri-implantitis treatment.
MATERIALS AND METHODS: Two hundred and eighty-one patient cases were selected consecutively from the archives of the Oral Microbiological Diagnostic Laboratory, Gothenburg, Sweden based on microbial analysis of bacterial samples taken from diseased implants. It was feasible to follow-up 245 patients after treatment for a period ranging from 9 months to 13 years.
RESULTS: In 54.7% of the patients it was not feasible to arrest progression of peri-implantitis. Smoking and smoking dose were found to be significantly correlated to failure of peri-implantitis treatment (p<0.05). Early disease development was also significantly associated with failure (p<0.05). Bone plasty in conjunction to antibiotics during surgery was significantly associated with arrested lesions (p<0.05). In a multiple regression model disease development was the only independent variable to significantly predict the likelihood of treatment success.
CONCLUSIONS: Peri-implant health may not be easy to establish, especially in cases that develop disease early. Homogenous treatment protocols rather than empirical treatment attempts should be adopted.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21770994     DOI: 10.1111/j.1600-051X.2011.01759.x

Source DB:  PubMed          Journal:  J Clin Periodontol        ISSN: 0303-6979            Impact factor:   8.728


  21 in total

1.  Peri-Implant Sulcus Fluid (PISF) Matrix Metalloproteinase (MMP) -8 Levels in Peri-Implantitis.

Authors:  René Thierbach; Kurt Maier; Timo Sorsa; Päivi Mäntylä
Journal:  J Clin Diagn Res       Date:  2016-05-01

Review 2.  Outcomes of implant therapy in patients with a history of aggressive periodontitis. A systematic review and meta-analysis.

Authors:  Charis Theodoridis; Andreas Grigoriadis; Georgios Menexes; Ioannis Vouros
Journal:  Clin Oral Investig       Date:  2016-12-24       Impact factor: 3.573

3.  Peri-implantitis. Part 2: Prevention and maintenance of peri-implant health.

Authors:  A Alani; K Bishop
Journal:  Br Dent J       Date:  2014-09       Impact factor: 1.626

4.  Reproducibility of subgingival bacterial samples from patients with peri-implant mucositis.

Authors:  Hadar Hallström; G Rutger Persson; Ulf Strömberg; Svante Twetman; Stefan Renvert
Journal:  Clin Oral Investig       Date:  2014-09-27       Impact factor: 3.573

Review 5.  Peri-implantitis. Part 1: Scope of the problem.

Authors:  A Alani; M Kelleher; K Bishop
Journal:  Br Dent J       Date:  2014-09       Impact factor: 1.626

6.  Vancomycin and tobramycin impregnated mineralized allograft for the surgical regenerative treatment of peri-implantitis: a 1-year follow-up case series.

Authors:  José Nart; Beatriz de Tapia; Àngels Pujol; Andrés Pascual; Cristina Valles
Journal:  Clin Oral Investig       Date:  2017-12-24       Impact factor: 3.573

7.  What is the prevalence of peri-implantitis? A systematic review and meta-analysis.

Authors:  Pedro Diaz; Esther Gonzalo; Luis J Gil Villagra; Barbara Miegimolle; Maria J Suarez
Journal:  BMC Oral Health       Date:  2022-10-19       Impact factor: 3.747

8.  Peri-implantitis. Part 3: current modes of management.

Authors:  A Alani; K Bishop
Journal:  Br Dent J       Date:  2014-10       Impact factor: 1.626

9.  Virulence factors and antibiotic susceptibility in enterococci isolated from oral mucosal and deep infections.

Authors:  Gunnar Dahlén; Susanne Blomqvist; Annica Almståhl; Anette Carlén
Journal:  J Oral Microbiol       Date:  2012-02-22       Impact factor: 5.474

Review 10.  Clinical efficacy of antibiotics in the treatment of peri-implantitis.

Authors:  Fawad Javed; Ali Saad Thafeed Alghamdi; Asma Ahmed; Toshinari Mikami; Hameeda Bashir Ahmed; Howard C Tenenbaum
Journal:  Int Dent J       Date:  2013-04-09       Impact factor: 2.607

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.